Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Crazy that I think the same thing. I lost a ton of money since Biden took office. This year I would be happy just to break even and be done with the stock market. Too much of a roller coaster ride for me.
H.C. Wainwright Bioconnect Conference!
Basically it’s a very important Conference for the company to its investors and future investors not RETAIL INVESTORS. This is a very important Conference for Zomedica, which will give us an idea what’s our next steps, where we heading towards, what’s the game plan for 2022. Stock price will probably get addressed because this is an Investor’s Conference, perhaps a buyback since it been on the table for more then a year already. It’s been approved by shareholders and Zomedica so let’s see what happens. ZM-020 Patent granted for 20 year on Aug 31, 2021.. as stated 20 years so expect them to push the product out as soon as possible.
The factual fact the market like Biden more! He’s more predictable actually! Old man goes with the flow.. tries to get his agenda done but clearly gets the foot.
I’m sorry you didn’t like my flippant response. Clearly, you can’t expect to be taken seriously when you’re posting nonsensically.
1. The SEC has taken no such action towards social media. No formal policy exists or has been enforced.
2. The random musing regarding the OTC is misplaced, may be better suited for an OTC board.
Coming up with some childish insult has literally zero effect on me or the validity of my statement. Pretending to have moral superiority or intellectual superiority will not help you either.
If you are unable to rebut my comments factually, just admit it and try to act dignified.
Make sure you stretch before you reach so hard...
Social Media pumping, Trump economy / economic policies, sell the rumor/buy the news effect.
I'm afraid we will be in a long trough now due to the Biden administration's anti-business, globalist policies, and the SEC taking a slightly tougher stance on social media pumping. I don't think we will see the OTC turn back around until we get a new administration into Office - and that depends on who that is and if the policies will help or hinder businesses.
Time to be greedy. Load the boats.
WTF??? How the heck was this POS ever at 2.90????
Well Hell yes. Pulsevet Revenue out $8.5M through September 30th, 2021 on pace to deliver around $11.3M annualized or 65% growth over 2020. With some positive news on additional assays we are ready to Pop. Looking forward to 2022.
Comments on a post from 3 months ago and calls it outdated. Lol.
$ZOM, loaded up some more $zom at .33/share. The future is promising. In two or three quarters, $zom will be at $3.00 then the sky us the limit. GLTA.
Just Hold! You’ll see.
He hold over a million of shares .. and he paid over 120k not under 100k.. what’s really remarkable that your so bearish but your keeping tabs. Keep showing real interests here!
What happens in April
If u are insider purchasing 97,000 dollars worth of stock doesn’t really impress anyone. Must not be a big believer in compsny
Spinoni …. There was an influx of hype back then that many investors listen too. Yea it was suppose to be 5 bucks by March 31st when product was going to be announced.
I did buy into
Stock but didn’t know about it till late and did pay over 2 dollats.
My biggest complaint was not being able to contact IR. They went to silent mode.
I called and emailed company several times over a 4 month period and never was able to make contact
So it was my bad. And it cost me big.
But I still see this continuing going down more. I see today it popped into the 4’d. It’s not to far away from its yearly low.
Plus it will be going down more this month. You got year end tax loss selling that many more will be getting out.
I got out earlier when finally realized it’s going to be quite a while before this stock could even get back up close to a dollar. I’m guessing if lucky from 1 1/2 to 2 years. You got to remember they still trying to put this company together
I do wish all of you that are holding the best of luck … I really mean that cause it’s no fun or enjoyable to be down on a stock for whatever reason
But sometimes you have to wake up and be realistic.
$$ZOM: April is coming. Get ready.
that was making up stores. the biggest loser so far
No denual $$Zom has potential for growth!
The following is from 2018, keep in mind the pandemic hit, and everything was slowed down.
Zomedica Provides Update on Pipeline Development and Announces At-The-Market Offering Program
December 20, 2018 17:23 ET
| Source: Zomedica Pharmaceuticals Corp.
ANN ARBOR, Mich., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today provided an update on its pipeline development and announced the entering into of an at-the-market equity offering sales agreement with Cantor Fitzgerald & Co.
“2018 was an industrious year in the development and expansion of our diagnostic pipeline alongside the continued development of our therapeutic candidates,” stated Gerald Solensky, Jr., Chairman and Chief Executive Officer at Zomedica. “We expect to provide study data, clinical data and key development insights throughout 2019 as we continue to work diligently on our pipeline.”
DIAGNOSTIC PIPELINE
ZM-024: Point-of-care diagnostic platform for performing immunodiagnostic testing
As previously announced, in November Zomedica partnered with Qorvo Biotechnologies, LLC (Qorvo) to collaborate on the development of a collection of rapid veterinary diagnostic assays for the performance of immunodiagnostic testing. Joint development work initially targets five assay candidates to detect certain thyroid and adrenal disorders in dogs and cats, which currently require reference lab immunoassay testing for reliable diagnostic results.
Zomedica expects to complete assay verifications for ZM-024 in Q4 2019, followed by validations in Q1 2020. Assuming successful completion of the development work, we expect to commence the marketing of this platform in the first half of 2020 for the initial five assay candidates, which we believe do not require pre-market regulatory approval by U.S. regulators.
ZM-024 is an investigational device, is not currently available for sale, and is limited to investigational use only.
ZM-020: Point-of-care pathogen detection platform
As previously disclosed, Zomedica is developing an in-clinic diagnostic analyzer with the potential to screen for pathogens in companion animals, beginning with fecal and urine samples.
In Zomedica’s early development work, the ZM-020 platform has successfully detected 13 unique urine pathogen signatures in water, including seven different gram positive and gram negative bacteria species and three types of crystals with greater than 93.93 percent sensitivity and 99.32 percent specificity in over 6,000 samples. Zomedica’s next development phase will seek to further optimize these results by moving beyond “spiked” water samples to automated detection of these signatures in urine samples. If development work progresses as anticipated, Zomedica expects to commence validation for its UTI assay and verification for its fecal assay in Q1 2019. We believe that ZM-020 does not require pre-market regulatory approval by U.S. regulators. Assuming that the development work is successfully completed, Zomedica expects to commence marketing ZM-020 in the first half of 2020.
We intend to develop additional applications for the ZM-020 platform, including further development of the pathogen detection library for urine and fecal analysis as well as for respiratory and dermatological analysis.
ZM-017: Circulating tumor cell assay platform for dogs
As previously disclosed, Zomedica is developing a circulating tumor cell (CTC) “liquid biopsy” diagnostic assay with the goal of enabling veterinarians to detect hard-to-diagnose canine cancers, such as hemangiosarcoma and osteosarcoma, with a simple blood draw. During the second half of 2018, Zomedica filed two provisional patent applications with the United States Patent and Trademark Office for its assay development activities and is working to optimize and verify additional assays for the ZM-017 platform.
Zomedica extended validation of its initial cancer assay after continued verification efforts, performed in parallel with early clinical validation steps during 2018, revealed opportunities to further optimize the assay to achieve broader commercial potential. In 2019, Zomedica expects to initiate verification and validation efforts for its blood-borne lymphoma cancer assay. Assuming successful completion of the clinical validation, we expect to commence the marketing of ZM-017 during the second half of 2020.
THERAPEUTIC PIPELINE
ZM-007 and ZM-012: Metronidazole for acute diarrhea in dogs
ZM-007 and ZM-012 are complementary oral formulations of metronidazole targeting the treatment of acute diarrhea in dogs. ZM-007 is an oral suspension for use with small dogs and puppies under nine pounds or four kilograms, currently only available via compounding pharmacies, while ZM-012 is a tablet formulation currently only available as a human generic.
Zomedica expects to commence a pivotal safety study for ZM-007 in the first half of 2019 and will pursue approval of ZM-012 as a bioequivalent to ZM-007, assuming that ZM-007 is approved by the Food and Drug Administration Center for Veterinary Medicine (FDA-CVM).
ZM-006: Transdermal methimazole for hyperthyroidism in cats
ZM-006 is a transdermal gel formulation of methimazole targeting the chronic treatment of hyperthyroidism in cats. Zomedica completed pilot testing to support our pivotal safety study in Q4 of 2018 and are analyzing the results. Zomedica expects to present and confirm the regulatory strategy and development plan for ZM-006 to the FDA-CVM in Q1 2019. Assuming that pilot testing is successful, Zomedica expects to commence the pivotal safety study in the first half of 2019. We also intend to initiate a pilot efficacy study in the first half of 2019.
ZM-011: Transdermal fluoxetine for behavioral disorders in cats
ZM-011 is a transdermal formulation of fluoxetine, most commonly known as Prozac®, intended to treat feline behavioral disorders, such as inappropriate urination. Zomedica believes that Fluoxetine continues to be a commonly compounded drug used by veterinarians. Pilot testing of ZM-011 to support our pivotal safety study was completed in 2018 and we are analyzing the results. Assuming that such pilot testing is successful, Zomedica expects to commence a pivotal safety study for ZM-011 in the second half of 2019.
MARKETING ACTIVITIES
As our development work progresses, Zomedica has also focused on building brand and product awareness as a valued veterinary partner with clinical practitioners. In Q4 2018, Zomedica initiated a strategic customer development initiative, which includes the expansion of its Voice of the Vet™ programming for veterinarians, veterinary technicians and nurses, practice managers and hospital administrators, as well as veterinary students. Zomedica also intends to provide educational white papers for its canine cancer diagnostic platform ZM-017 and its point-of-care pathogen detection platform ZM-020 in early 2019.
SHELF REGISTRATION STATEMENT AND AT-THE-MARKET OFFERING PROGRAM
Zomedica also announced that it has filed with the United States Securities and Exchange Commission (SEC) a universal shelf registration statement on Form S-3 covering the issuance and sale in the United States from time to time of up to $300.0 million of its securities. In connection therewith, Zomedica also entered into an at-the-market equity offering sales agreement with Cantor Fitzgerald & Co., effective as of December 20, 2018, under which Zomedica may sell pursuant to the universal shelf registration statement common shares in the United States only, from time to time, for up to $50.0 million in aggregate sales proceeds in "at the market" transactions.
The registration statement has been filed but has not been declared effective by the SEC. No sales of the securities covered by the registration statement, including sales of common shares pursuant to the sales agreement, may be made prior to the effectiveness of the registration statement. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities being offered, nor may there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or other jurisdiction.
Buying opportunities .. thanks for the wishes.. cut the FUD tho
your lower 550's have now become your lower 40's
I thought you claimed this was turning around with the new ceo.
I still wish you and all the best... i sincerely mean that
It just not for me with the old ceo that went to head of board... he still has influence over new cceo and i lost all my trust when he was the ceo and went silent.
It wasnt just me i know many others that left too for that reason.
Insiders buying they know it's undervalued.
Keep lurking with full pipeline Zomedica should be valued at 40 billion
Keywords PIPELINE ZM-017 / ZM-020 on the way
Bro he is fully retired.. he came in as a interm ceo and did an amazing job we are sitting on 200m in cash lol
Insider buying board member buys 250k shares at 45 cents he’s averaging up I think you should be to.. it was an option exercise it was cash purchase for over 100k
A lot of patent news on ZM-017/ZM-020
Over 40 PDF files filed yesterday and today! Reason behind insider purchasing 250k shares
Never thought it would go below.50. I nice piece of good news which we haven’t had in a while can send us in the right direction.
As with any stock it always depends on when you enter. Any loss is clearly not preferred and met with all kinds of excuses, and negatively. If things were opposite the same wouldn’t hold water. I’m still up 10% and although one could add all the reasons to be negative I’ll ride this out a bit longer. Looking at some institutional buying, and current trades not all are doom and gloom. Best of luck for all.
I’m down 77%. $ZOM better bounce back, or no Christmas for me. ??
Yeah, I am down 67% here myself. Have averaged down 8 different times, and the SP has fallen after every single one of those times as well. So I am fearful of the bottom being......... bottomless.
I guess it was a fluke to hit $2.91 cents back in February or was it March? Coulda, woulda, shoulda sold back then but who knew?? Even though it fell back down since then, I never thought it would be this low at this point. But anything can change in an instant, just trying to remain positive. GLTU
Eyal you are one of the best of the loyals. I know u done ur DD and believe in the stock/company. Many of us do not. Ur former ceo in my opinion ran too many off with their silence. Especially back in feb on thru summer when I finally got out
You hang in there. I do wish the best for you and the others but I still don’t see dollarland for another year or 2. And then that will require sone luck
Let see how that work out for yall.. Zomedica can't R/S .. they can buy the float back at 30 cents, their cash value for share price is at 30 cents.. you guys are smoking crack.. keep entertaining me
I honestly can't put a number on it right now. I don't think this thing has a bottom yet, and won't for a while. They've been too quiet and there's been no real progress on selling anything all this year since March - and they haven't said they have anything else in the pipeline that I'm aware of. I would guess without any real revenue they aren't going anywhere but down for a while.
Where do you see ZOM as a buy?
It’s on drugs! Rev is for crack heads!
Yep. This one has no real revenue and hasn't made any progress in getting out into the market in almost a year. I don't think this has a bottom to it at the moment.
Wow…. So much for 50 cent support.
The ZOM bomb just hit 45 cents.
It’s not unicorns and butterfly’s …They all will find out soon.
Let’s save these posts and check back in 6 months from now.
Keep dreaming. Zomedica is about to close another acquisition. The fantasy of an RS is only a shorts-wet dream. Do your homework know what you own.
I disagree with almost this entire post. This one is going lower and will need to do a RS soon.
What a shame they had some good momentum going but fell victim to the OTC market crash. I suspect things will stay depressed like this for about 3.5 more years.
Does anyone have any insight into what $zom is planning for its SECOND acquisition?
Stop feeding into the narrative guys and make your own!
Key Points
•Zomedica Corp current quarter revenue growth YoY of 123.40% ranked 438 out of 5660 companies
•Weekly/2-4HR Golden Cross.. citadel closed its position here a day before the RICO was filed.
•The R&D expenses reached $0.3M, implying a ~89% decline with the completion of TRUFORMA development. However, SG&A expenses soared ~165% YoY to $6.1M, driven by a $1.5M share-based compensation expense during the period.
•09/2020 144 units placed is more then 2x Last Quarter
•Earning don’t mean shit until they do
•Paperhands show fear and feed down the social sentiment
•Bots and Algo see this and start putting pressure in this group, Stocktwits, Twitter, in all social media platforms.
•The reasons Zomedica is going to be uptrending and has been for past two month $IWM $IWO, we being pushed and the tree will be shaking on multiple occasions like last night. Micro/Small cap in general is going higher going into 2022.
•To sell afterhours you need a buyer so stop the fear, This is a accumulation tactic even a cover attempt.
•The market is in rotation currently and a lot of hedgies are gonna get fucked with their FTD (Fail to Deliver) liquidations are happening and more to come.
•Citadel Closed its full position in @Zomedica on 08/16
•Citadel was charged in RICO case for racketeering on 08/17
•Zomedica is targeting VetCor Banfield Pet Hospital VCA Animal Hospitals
•Share Buy backs are trending current shorts hold 120m in shares I expect Zomedica to buy 100M in shares for under 60M at 50 cent support level which Market Makers made clear to short seller and Zomedica board team when it hit 44 cents and shot to 80 cents.. I found support at 50 cents for the third/fourth time which is a real triple bottom
•ZM-017 Patent is in Final Stages 10/21
•ZM-020 mentioned in Q3 10-k last night
•Larry Heaton used a keyword in his report saying Pulsevet ???? Housecalls Veterinary Centre PulseVet was the “FIRST” acquisition by Zomedica.
•2022 Global Sales Expansion
•200M in Cash Reserves [War Chest]
•50 cents been a key support since 2017 [IPO], should say a lot with current share buy back trend, R/S impossible, moving the company is impossible to Delaware we should see 50/60M dollar buy back by Zomedica because they won’t have this chance again and not like last time they actually have the extra funds to do it and acquire another company with approximately 5 years of funding still left in their War Chest for expenses, r&d, employees
•Cash Flow positive by 2023
•Our true valuation in 2023 should be around 40 Billion with full diagnostic pipeline with current float should put your Price Target on Zomedica in 2023 at $40 a share
•Valuations don’t matter until they do, earnings don’t matter until they do, Citadel short laddered the stock down with a bunch of other “MEME” stocks.. they all run the same Algo as I said in April of 2020. Don’t let the FUD scare you!
•2020 4400% gains from 6 cents to $2.80, if we get those same numbers it’s $20 a share.. $5/6 is a healthy target!
•Zomedica isn’t only going to compete but it will complete the veterinary sector.
•130k Followers on Stocktwits, 380k on Webull a lot of eye on Zomedica.
•Citadel has ownership in Facebook, Stocktwits, Twitter they have eyes and bots everywhere and their one of many short sellers that have bots on social platforms debunking Zomedica. They pay stock media outlets to release articles that benefit them because it also benefits their investors which is JP, Vanguard, BlackRock as they take advantage by averaging down on their Long Term positions as seen after April very heavy institutional sentiment going into Q2 & Q3.
Follow me on Discord at Discord.gg/banlvl3
Learn to Trade & partnered alerts
Follow me on Twitter for most update data on Zomedica and my trades/positions @EYALCap
Followers
|
196
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3195
|
Created
|
01/26/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |